Mind Cure Health Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pablo Navarro
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 422 Richards Street Vancouver BC Canada V6B 2Z4
- IPO Date
- Jan 8, 2021
- Website
- mindcure.com
- Similar Companies
- Business
- Mind Cure Health Inc. (Ticker: MCURF) develops and commercializes digital therapeutics and software solutions focused on mental health treatment, particularly for conditions such as anxiety, depression, and PTSD; its core offerings include the MindCure NOW platform for patient self-guided therapy sessions, the MindMesh clinician portal for remote monitoring and personalized treatment plans, and breakthrough-assisted therapies integrating AI-driven insights with psychedelic-assisted psychotherapy protocols. The company provides subscription-based software-as-a-service models to healthcare providers, clinics, and direct-to-consumer channels, emphasizing evidence-based digital tools validated through clinical trials. Founded in 2020 and headquartered in Vancouver, Canada, Mind Cure Health operates primarily in North America with expanding partnerships in Europe and Australia, targeting behavioral health networks, telemedicine platforms, and wellness enterprises. In late 2024, the company secured a C$10 million funding round led by strategic healthcare investors to accelerate platform enhancements and regulatory approvals for new AI-enhanced modules; it also announced a key acquisition of a complementary AI diagnostics firm in early 2025, bolstering its data analytics capabilities, and launched the MindCure PRO enterprise suite for large-scale clinic deployments amid growing demand for scalable mental health tech solutions.
MINDCURE to Participate in Upcoming Conferences in December 2021
MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021
OTC Markets Group Welcomes Mind Cure Health Inc. to OTCQX
MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy
MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers
MINDCURE Announces Inclusion in AdvisorShares Psychedelics ETF
MINDCURE to Participate in Maxim Group LLC's Advances in Mental Health Virtual Conference
MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry
MINDCURE Announces Platinum Sponsorship of the 2021 SANA Symposium
MINDCURE to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MINDCURE Announces Financial Results for Fiscal 2021
MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America
MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor
MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM